S-1: Calidi Biotherapeutics Files S-1 for Resale of Shares, Highlights Clinical Progress and Ongoing Funding Needs Amidst Significant Losses

Calidi Biotherapeutics, a clinical-stage biotechnology company, filed an S-1 registration statement for the resale of up to 6.35 million common shares, detailing its novel oncolytic virus platforms, recent management changes, and persistent financial challenges including substantial operating losses and a going concern warning.

Summary

• Calidi Biotherapeutics is a clinical-stage biotechnology company developing genetic medicines and proprietary genetically-engineered oncolytic viruses for oncology.
• The company's key platforms include RedTail, an enveloped vaccinia virus platform for systemic delivery of genetic medicine to tumor sites, and two stem cell-based oncolytic virus platforms, SuperNova and NeuroNova.
• RedTail is expected to commence a Phase I trial by the end of 2026 with its first compound, CLD-401, designed to deliver IL-15 superagonist to the tumor microenvironment.
• The NeuroNova investigational drug candidate is currently in a Phase 1 trial with partner City of Hope, and an IND is open for a Phase 1 trial for the SuperNova investigational drug candidate.
• The company has incurred significant operating losses since its inception, with a net loss of approximately $5.1 million for the three months ended March 31, 2025, and an accumulated deficit of approximately $126.7 million as of March 31, 2025.
• Cash and restricted cash totaled $10.6 million and $0.2 million, respectively, as of March 31, 2025, with working capital of approximately $6.1 million.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern within 12 months from March 31, 2025, due to recurring losses and the need for additional funding.
• Recent capital raises include $4.3 million gross proceeds from a January 2025 public offering and $3.9 million gross proceeds from a March 2025 registered direct offering and concurrent private placement.
• Allan Camaisa resigned as CEO and Chairman effective April 21, 2025, transitioning to CEO Emeritus and remaining a Class III director, with Eric Poma, Ph.D. appointed as the new CEO and Class I director, and James Schoeneck appointed Chairman of the Board.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, including recurring losses, a significant accumulated deficit, and a stated 'substantial doubt' about its ability to continue as a going concern. While there are promising preclinical programs and recent capital raises, the immediate financial viability is highly uncertain, and existing funding is insufficient for the next 12 months. The stock price is very low, and dilution is a significant ongoing risk.

Positives

• The company is developing three novel oncolytic virus platforms (RedTail, SuperNova, NeuroNova) designed to overcome immune clearance, a major obstacle for oncolytic virus therapies.
• Preclinical studies for RedTail have shown promising results, including systemic administration, targeting of metastatic sites, delivery of genetic medicines, and complete tumor eradication in mouse models when combined with its genetic payload.
• An IND is open for a Phase 1 trial for the SuperNova investigational drug candidate, and NeuroNova is already in a Phase 1 trial with City of Hope.
• The company has a robust patent portfolio covering its technology platforms and product candidates, with potential patent coverage extending to 2038 and 2045 for some families.
• The appointment of Dr. Eric Poma as CEO brings a highly accomplished physician-scientist with extensive industrial and academic experience in Immuno-Oncology and oncolytic viruses to lead the company.
• The company has successfully raised capital through recent public and private offerings in January and March 2025, totaling approximately $8.2 million in gross proceeds.

Negatives

• The company is a clinical-stage biotechnology company with a limited operating history and has not generated any revenue from product sales to date.
• Significant operating losses have been incurred since inception, with a net loss of $5.1 million for Q1 2025 and an accumulated deficit of $126.7 million as of March 31, 2025.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern within 12 months from March 31, 2025, necessitating significant additional funding.
• The company's ability to obtain future financing is uncertain and may result in substantial dilution to existing stockholders, as well as potentially unfavorable terms.
• The Forward Purchase Agreements are unlikely to yield any funds to the company due to the current trading price being significantly below the initial $100 per share reset price and a $20.00 per share reduction adjustment.
• The CLD-101 product for newly diagnosed HGG is currently on hold as the company prioritizes other product candidates, indicating a delay in that specific program.

Risks

• The company has a limited operating history, has not generated any revenue from product sales, and anticipates continued significant operating losses for the foreseeable future.
• The company needs to raise substantial additional funding to support its operations and product development programs; inability to do so would force delays, reductions, or cessation of operations.
• The engineered RedTail platform and allogeneic stem cell product candidates represent novel approaches to cancer treatment, creating significant challenges in manufacturing, regulatory approval, and potential immune-related adverse events.
• Adverse publicity regarding viral-based or genetic therapies, particularly stem cell-based immunotherapy, could materially impact the business and ability to raise capital.
• Preclinical studies and clinical trials may fail to demonstrate adequate safety and efficacy, leading to delays or prevention of regulatory approval and commercialization.
• Interim, top-line, and preliminary clinical trial data may change as more patient data become available and are subject to regulatory audit and verification, potentially resulting in material changes in final data.
• The company faces substantial competition from major pharmaceutical and biotechnology companies with significantly greater financial resources and expertise.
• The regulatory approval processes are lengthy, time-consuming, and inherently unpredictable, with no assurance of timely approval or commercialization.
• Failure to comply with continued listing standards of the NYSE American could lead to delisting, negatively impacting stock value and liquidity.
• The company is exposed to product liability claims from clinical trials and future product sales, with potential for substantial liability exceeding insurance coverage.
• The company is subject to various healthcare laws and regulations (e.g., Anti-Kickback Statute, False Claims Act, HIPAA), and non-compliance could lead to significant penalties and reputational harm.
• Reliance on third-party manufacturers and CROs exposes the company to risks of supply delays, quality control issues, and non-compliance with cGMP regulations.
• The increasing use of social media presents risks of liability, data security breaches, and reputational damage from inappropriate disclosures or negative comments.
• Changes in U.S. and international trade policies, including scrutiny of the Chinese biopharmaceutical industry, could adversely impact manufacturing and business operations.
• The company's internal computer systems or those of third parties are vulnerable to security breaches, which could disrupt development programs and lead to data loss or inappropriate disclosure.

Future Outlook

The company expects to continue incurring significant and increasing operating losses for the foreseeable future as it advances product candidates through preclinical and clinical development, seeks regulatory approval, and expands its intellectual property portfolio. It will need substantial additional funding to support continuing operations and growth, as existing cash is not sufficient for the next 12 months. The RedTail platform is expected to commence a Phase I trial by the end of 2026, and a Phase 1 clinical trial for CLD-201 is anticipated during the first half of 2025. The company aims to generate revenue from product sales only after successful clinical development and regulatory approval, which is not expected in the near future.

Management Comments

• Allan Camaisa notified the Board of his resignation as CEO and Chairman, effective April 21, 2025, stating it was not due to any disagreement with the company or its Board.
• Dr. Eric Poma was appointed CEO of the company, effective April 22, 2025.
• James Schoeneck was appointed Chairman of the Board, effective April 22, 2025.
• Management believes they do not have sufficient cash on hand to support current operations for at least one year from March 31, 2025, and will need to raise additional capital.

Industry Context

Calidi Biotherapeutics operates in the highly competitive and rapidly changing immuno-oncology and biotechnology industries, specifically focusing on oncolytic viral immunotherapy. This field is characterized by high degrees of uncertainty and risk, with few viral immunotherapies having received global or FDA approval to date. The company's novel approach using stem cell-based and enveloped virus platforms aims to address the major obstacle of rapid immune elimination faced by traditional oncolytic viruses. Competitors include large pharmaceutical and biotechnology companies like AstraZeneca, Bristol-Myers Squibb, Merck, Novartis, Pfizer, and Roche/Genentech, as well as other viral immunotherapy developers such as Oncorus, Replimune, Amgen, and IconOVir. The industry is also subject to increasing legislative and regulatory scrutiny regarding drug pricing and healthcare costs.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit filed on November 15, 2023, by Tony Kalajian (former Chief Accounting Officer and interim Chief Financial Officer) against the company, Allan Camaisa, and Wendy Pizarro, alleging defamation and constructive discharge, seeking $575,000 in damages, punitive damages, and attorneys' fees. The company denies the allegations and is seeking recovery of a $150,000 bonus Mr. Kalajian approved for himself. The case was stayed but the stay was lifted in March 2025.
• A lawsuit filed on October 29, 2024, by Mr. Yian Zeng against the company alleging securities fraud, breach of covenant of good faith and fair dealing, unjust enrichment, restitution, breach of fiduciary duty, and constructive fraud. The company denies all claims, and a mandatory settlement conference on April 9, 2025, resulted in no resolution.
• A lawsuit filed on March 14, 2022, by certain physicians regarding unexercised stock options was settled on February 9, 2024. The settlement involved the issuance of 20,000 restricted shares of common stock and 40,000 warrants to purchase restricted shares.

Related Party Transactions

• As of March 31, 2025, $1.1 million in related party term notes payable (principal and accrued interest) were due to Directors A, classified as a short-term liability. As of December 31, 2024, this amount was $2.7 million due to Directors A and E.
• Amounts owed to AJC Capital and a relative of Officer A for reimbursable expenses and legal fees totaled $43,000 as of March 31, 2025, and $30,000 as of December 31, 2024. $28,000 was settled with AJC Capital in April 2025.
• A severance accrual and accrued interest of $434,000 was due to George K. Ng (former President and COO) as of December 31, 2024, which was settled in January 2025.
• Accrued advisory fees of $18,000 were due to Director A (Scott Leftwich) as of December 31, 2024, which were settled in January 2025.
• A personal Guaranty of Lease of up to $0.9 million was provided by Allan Camaisa (former CEO) for the San Diego Lease, with the company obligated to pay him 10% of the Guaranty amount for the first year and 5% per annum thereafter, accrued and payable at termination or release of Guaranty. The present value of this obligation was $190,000 as of March 31, 2025.
• An agreement with Director A for deferred compensation including advisory fees for $0.5 million was paid in January 2025. This note bore interest at 24% through August 12, 2024, then 14% per annum.
• Warrant liabilities of $6,000 as of March 31, 2025, and $9,000 as of December 31, 2024, were associated with AJC Capital and Director A.
• A loan payable of $0.2 million to a relative of Officer A, bearing 12% interest, was entered into in January 2024 and settled in full in January 2025.
• A strategic investment of approximately $2.0 million by a related-party investor into Nova Cell, a subsidiary, in exchange for 7,500,000 shares (25% ownership) of Nova Cell's common stock on July 26, 2024.

Stakeholder Impact

• **Shareholders:** Face significant dilution from ongoing and future equity offerings, as well as potential stock price volatility due to the company's financial condition and the large number of warrants outstanding. Existing shareholders who purchased at higher prices may not realize similar profits as early investors.
• **Employees:** The company's ability to attract and retain qualified personnel is critical to its success, but the ongoing financial challenges and going concern warning could impact employee confidence and retention.
• **Patients:** The development of novel oncolytic virus therapies offers potential new treatment options for cancer patients, but clinical trial failures, safety concerns, and delays could impact patient access to these therapies.
• **Creditors:** The company's recurring losses and substantial doubt about its ability to continue as a going concern raise concerns about its capacity to meet contractual obligations, potentially affecting creditors.
• **Regulatory Bodies:** The company's operations are subject to extensive and evolving regulatory requirements, and non-compliance could lead to sanctions, fines, or delays in product development and commercialization.

Next Steps

• Advance current and future product candidates through preclinical and clinical development.
• Seek regulatory approval for product candidates.
• Manufacture drug product and drug supply for clinical trials.
• Maintain and expand the intellectual property portfolio.
• Hire additional research and development and business personnel.
• Obtain substantial additional funding through public or private equity offerings, debt financings, or collaboration agreements to support continuing operations and growth.
• Commence a Phase 1 clinical trial for CLD-201 during the first half of 2025.
• Submit to the FDA for the RedTail product candidate for a Phase 1 clinical trial by the end of 2026.
• Continue to pursue cost-efficient manufacturing processes for allogeneic stem cell therapeutic candidates.
• Pursue opportunistic out-licensing of stem cell-derived products.

Key Dates

Recommendation

Keywords

Biotechnology, Oncology, Genetic Medicines, Oncolytic Viruses, RedTail, SuperNova, NeuroNova, Clinical Stage, Cancer Treatment, SEC Filing, S-1, Capital Raise, Dilution, Going Concern, Immunotherapy, Vaccinia Virus, Adenovirus, Stem Cells, Clinical Trials, Drug Development